AUTONOMOUS TECHNOLOGIES SCHEDULED FOR
FDA PANEL REVIEW IN FEBRUARY
ORLANDO, Fla., JANUARY 13, 1998, AUTONOMOUS
TECHNOLOGIES CORPORATION (NASDAQ NM: ATCI) today
announced that the Ophthalmic Devices Panel of the U.S. Food and
Drug Administration (FDA) will review the Company's premarket
approval application (PMA) for the Autonomous LADARVision(r)
System on February 13, 1998. The PMA submission encompasses
myopia with astigmatism of up to -10 diopters of myopic refractive
error.
Commenting on the FDA's announcement, Randy Frey, President
and CEO of Autonomous Technologies, stated, "We look forward to
supporting our compelling data at the FDA panel meeting in
February. Our PMA team has worked effectively to put Autonomous
in this strong position and I congratulate them for a job well done. As
we approach the most important milestone of our Company's history,
we are committed, as always, to providing superior technology and
better results for a broader range of patients."
The FDA Ophthalmic Advisory Panel reviews the PMA application for
approvability. The FDA accepts the advice of the Panel, but is not
necessarily bound by its decision.
Autonomous Technologies is engaged in the design and development
of next-generation excimer laser instruments for laser refractive
surgery. The Company's LADARVision System combines high
speed, laser radar eye tracking with precisely controlled narrow beam
shaping technology.
The statements in this press release which express belief,
anticipation, or expectations, as well as other statements which are
not historical fact, are forward looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 and involve
risks and uncertainties that could cause actual results or
performance of the Company to differ materially from the results or
performance described herein. Please see the Company's filings with
the Securities & Exchange Commission for a statement of certain
risks and uncertainties.
# # # |
